Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S357000, C514S383000, C514S399000, C514S439000, C514S464000, C514S563000, C514S637000, C514S538000, C546S194000, C546S280700, C546S281100, C546S316000, C548S267200, C548S335500, C548S494000, C548S532000, C548S540000, C549S074000, C549S434000, C562S440000
Reexamination Certificate
active
07928137
ABSTRACT:
Compounds of formula Iin which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.
REFERENCES:
patent: 3202654 (1965-08-01), Perron
patent: 3536726 (1970-10-01), Fink et al.
patent: 4000134 (1976-12-01), Dolfini
patent: 6080767 (2000-06-01), Klein et al.
patent: 6498165 (2002-12-01), Armstrong et al.
patent: 6545055 (2003-04-01), Zhu et al.
patent: 6638980 (2003-10-01), Su et al.
patent: 6916957 (2005-07-01), Lively et al.
patent: 0122157 (1984-10-01), None
patent: 0483667 (1992-05-01), None
patent: 0540051 (1993-05-01), None
patent: 0588655 (1994-03-01), None
patent: 0672658 (1995-09-01), None
patent: WO 92/08709 (1992-05-01), None
patent: WO 94/29336 (1994-12-01), None
patent: WO 95/13274 (1995-05-01), None
patent: WO 97/24118 (1997-07-01), None
patent: WO 97/24135 (1997-07-01), None
patent: WO 97/36859 (1997-10-01), None
patent: WO 00/71507 (2000-11-01), None
patent: WO 00/71508 (2000-11-01), None
patent: WO 00/79453 (2000-11-01), None
Liebeschuetz et al. “Preparation of meta- . . . ” CA 130:237884 (1999).
Hatanaka, M. et al. “Synthetic Penicillins. Heterocyclic Analogs of Ampicillin. Structure-Activity Relationships”, J. Med. Chem. 16(9) pp. 978-984 (1973).
R. Ferroni et al; 1 Farmaco Ed Sci (1987)42(10)pp. 709-715. (Chemical Abstracts, vol. 108 No. 7 Dec. 23, 1985 Columbus, Ohio, US; Abstract No. 48724q. XP00208333.
R. Ferroni et al; l1 Farmaco Ed Sci (1985)40(10)pp. 717-729. (Chemical Abstracts, vol. 103, No. 25, Dec. 23, 1985 Columbus, Ohio, US; Abstract No. 209699z, XP002083330).
J. Sturzebecher et al; Thrombosis Research (1976)9(6)pp. 637-646.
Alig et al. “Low molecular weight, nonpeptide fibrinogen receptor antagonists” CA 118: 7363, (1993).
B. R. Baker et al; Journal of Medicinal Chemistry, vol. 12, No. 3, 1969, p. 408-414, Washington US. (Chemical Abstracts, vol. 71, No. 7 Aug. 18, 1969, Columbus, Ohio, US; Abstract No. 28982m,XP002083332).
H. Vieweg et al; Pharmazie, vol. 38, No. 12, 1983, p. 818-820 Berlin DE. (Chemical Abstracts, vol. 101, No. 1, Jul. 2, 1984, Columbus, Ohio, US; Abstract No. 6764c, XP002083333).
Jones Stuart Donald
Liebeschuetz John Walter
Morgan Phillip John
Murray Christopher William
Rimmer Andrew David
Chang Celia
Friedrichsen Bernard P.
Tularik Limited
LandOfFree
Meta-benzamidine derivatives as serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Meta-benzamidine derivatives as serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Meta-benzamidine derivatives as serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699008